Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Adaptive Phase II/III Study of Abatacept Plus Mycophenolate Mofetil in Lupus Nephritis
2005-004575-37Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) and lupus nephritis (LN) comparing Abatacept + Mycophenolate Mofetil with Placebo + Mycophenolate Mofetil (2 arms). Primary endpoint: Time to complete renal response. Started Mar 2007; status: completed.
02
Drugs
abatacept
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on 2005-004575-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004575-37.